Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Keith Wonnacott"'
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 21, Iss , Pp 524-529 (2021)
The rapid expansion of the gene therapy pipeline in recent years offers significant potential to treat diseases with great unmet medical need. However, the unique nature of these therapies poses challenges to regulating them within traditional framew
Externí odkaz:
https://doaj.org/article/8dacb75294d34035838ec7670d14bd1c
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 4, Iss C, Pp 92-101 (2017)
Immunotherapy using chimeric antigen receptor-modified T cells has demonstrated high response rates in patients with B cell malignancies, and chimeric antigen receptor T cell therapy is now being investigated in several hematologic and solid tumor ty
Externí odkaz:
https://doaj.org/article/f1b3c78e484d46f8b533868318002c37
Autor:
Nathalie Lambot, Jacquelyn Awigena-Cook, Tatiana Reimer, Annelie Persson, Julien Romanetto, Beatrix Friedeberg, Virginia Acha, Shera Dandapat, Thorsten Ruppert, Caroline Correas, Keith Wonnacott, Tobias Fleischmann, Christa Holzhauser, Ariane Galaup, Fátima Montes, Silvia Garcia, Pär Tellner, Stuart G Beattie
Publikováno v:
Cell and Gene Therapy Insights. 7:1093-1106
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 4, Iss C, Pp 92-101 (2017)
Molecular Therapy: Methods & Clinical Development, Vol 4, Iss C, Pp 92-101 (2017)
Immunotherapy using chimeric antigen receptor-modified T cells has demonstrated high response rates in patients with B cell malignancies, and chimeric antigen receptor T cell therapy is now being investigated in several hematologic and solid tumor ty
Autor:
Bruce S. Schneider, Evgenij Evdokimov, Larisa Rudenko, Cheng-Hong Wei, Phillip J. Snoy, Allen K. Wensky, Jeff Jones, Judith Arcidiacono, Mark H. Lee, Keith Wonnacott
Publikováno v:
Xenotransplantation. 17:329-337
The use of xenogeneic porcine pancreatic islets has been shown to be a potentially promising alternative to using human allogeneic islets to treat insulin-dependent type 1 diabetes (T1D). This article provides an overview of the existing FDA regulato
Autor:
Keith Wonnacott, Caitilin A. Hamill, Judith Arcidiacono, Steven S. Oh, Martha A. Wells, Anastacia M. Bilek, Mark H. Lee, Jeremiah J. Wille
Publikováno v:
Tissue Engineering Part B: Reviews. 16:41-54
Tissue-engineered and regenerative medicine products are promising innovative therapies that can address unmet clinical needs. These products are often combinations of cells, scaffolds, and other factors and are complex in both structure and function
Autor:
Judith A, Arcidiacono, Evgenij, Evdokimov, Mark H, Lee, Jeff, Jones, Larisa, Rudenko, Bruce, Schneider, Phillip J, Snoy, Cheng-Hong, Wei, Allen K, Wensky, Keith, Wonnacott
Publikováno v:
Xenotransplantation. 17(5)
The use of xenogeneic porcine pancreatic islets has been shown to be a potentially promising alternative to using human allogeneic islets to treat insulin-dependent type 1 diabetes (T1D). This article provides an overview of the existing FDA regulato
Autor:
Keith Wonnacott
Publikováno v:
American journal of therapeutics. 12(6)
Over the past 12 years, the US Food and Drug Administration (FDA) has reviewed more than 40 investigational new drug applications for the use of allogeneic pancreatic islets to treat type 1 diabetes mellitus. Recent advances in islet cell isolation,
Publikováno v:
Handbook of Cancer Vaccines ISBN: 9781468498189
The progress made over the last few decades in understanding the genetic and immunological aspects of cancer has led to the development of a large number and variety of immune-based approaches to combat the disease. Among the products developed, or u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af19a7e07bee294d386a0dd371e759bb
https://doi.org/10.1007/978-1-59259-680-5_37
https://doi.org/10.1007/978-1-59259-680-5_37
Publikováno v:
Cell Stem Cell. (2):141-145
Proposals submitted to the FDA for MSC-based products are undergoing a rapid expansion that is characterized by increased variability in donor and tissue sources, manufacturing processes, proposed functional mechanisms, and characterization methods.